News | Proton Therapy | May 31, 2018

Beaumont Researchers Invent New Mode of Proton Treatment for Lung Cancer

Continuous arc treatment significantly reduces adverse effects of respiration-induced motion on lung cancer patients

Beaumont Researchers Invent New Mode of Proton Treatment for Lung Cancer

May 31, 2018 — Members of Beaumont Health’s proton therapy team presented research on a new treatment for patients with lung cancer at the recent European Society for Radiotherapy and Oncology (ESTRO) 37 Congress, April 20-24 in Barcelona, Spain.

“Beaumont researchers have invented a new mode of proton therapy for lung cancer,” said Peyman Kabolizadeh, M.D., Ph.D., clinical director, Beaumont Proton Therapy Center in Royal Oak. “A continuous proton arc treatment can significantly reduce the adverse effects of respiration-induced motion on lung cancer treatments. This advancement will also result in a better and lower dose of radiation to adjacent organs.”

Explained Kabolizadeh, “The promising results might lead to interest and future development of the proton arc therapy technique. Beaumont continues to be a center of new treatment development through research.”

Proton therapy is a high-tech alternative to X-ray radiation. A scanning beam of proton radiation with online image guidance offers greater precision to destroy cancerous cells, sparing adjacent healthy tissue with fewer side effects.

Proton therapy uses positively charged atomic particles, traveling up to two-thirds the speed of light, to fight cancer. A cyclotron, or particle accelerator, creates protons from hydrogen molecules. The proton beam is sent to the treatment room through a transport system consisting of magnets, called the beam line, finally arriving in the gantry, a device that rotates around the patient. The beam is directed to the patient through a nozzle that targets the tumor.

While proton therapy is not effective against all cancers, it is effective in treating many solid and localized tumors.

Beaumont’s center is one of just 28 proton therapy centers in the U.S. It is the only operational proton therapy center in Michigan. Beaumont doctors have treated or consulted with patients across Michigan and 11 other states since opening the Proton Therapy Center in 2017.

“Our IBA Proteus One single-room treatment system includes precision technologies,” said Kabolizadeh. “Intensity modulated proton therapy with pencil beam scanning technology and 3-D cone beam CT [computed tomography], can target a tumor within less than a millimeter.”

Pencil beam scanning (PBS) refers to the delivery of protons in a thin beam. Like a pencil, the beam uses back and forth motions to target the treatment area – the shape, size and depth — painting a radiation dose on tumors layer by layer. Compared to X-ray beams, which pass through a patient, proton beams deliver targeted radiation to the tumor and then stop – resulting in no exit dose.

For more information: www.beaumont.org

Related Content

Accuray Incorporated announced that Mercy Hospital St. Louis continues to demonstrate its commitment to improving patient outcomes with the installation of the first CyberKnife M6 System in Missouri at their state-of-the-art David C. Pratt Cancer Center
News | Stereotactic Body Radiation Therapy (SBRT) | February 27, 2020
February 27, 2020 — Accuray Incorporated announced that Mercy
Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure

Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure. This picture shows a circle of hydrogel that was irradiated on the left half, which is slightly pink; whereas the right half of the gel is not irradiated and remains colorless.

News | Radiation Therapy | February 18, 2020
February 18, 2020 — More than half of all cancer patients undergo radiation therapy and the dose is critical.
Varian announced it has received FDA 510(k) clearance for its Ethos therapy, an Adaptive Intelligence solution. Ethos therapy is an artificial intelligence (AI)-driven holistic solution that provides an opportunity to transform cancer care.
News | Image Guided Radiation Therapy (IGRT) | February 11, 2020
February 11, 2020 — Varian announced it has received FDA 510(k) c
The radiation therapy market is projected to grow in through 2026

Image courtesy of Accuray

News | Proton Therapy | February 10, 2020
February 10, 2020 — Amid technological advancement, and notable research and development activities, the global ...
Accuray TomoTherapy total body irradiation
News | Radiation Therapy | February 07, 2020
February 7, 2020 — Accuray Incorporated announced that two new studies demonstrate the benefits of the ...
The luminescent oxygen probe PtG4 is injected during the week of radiation treatment and localizes between the cells of the tumor as illustrated by microscopy

An oxygen map image recovered from a mouse undergoing radiation therapy. The luminescent oxygen probe PtG4 is injected during the week of radiation treatment and localizes between the cells of the tumor as illustrated by microscopy (red). Image courtesy of Brian Pogue, PhD

News | Radiation Therapy | February 03, 2020
February 3, 2020 — Oxygen in cancer tumors is known to be a major factor that helps radiation therapy be successful.
IBA ProteusOne proton therapy system
News | Proton Therapy | January 29, 2020
January 29, 2020 — IBA (Ion Beam Applications S.A.) announced that it has signed a contract and received a major down
Pulmonary imaging is important in the diagnosis of the acute lung injury associated with vaping, known as electronic cigarette or vaping product use-associated lung injury (EVALI), according to a special review article published in the journal Radiology

Images show electronic cigarette or vaping product use-associated lung injury in a 32-year-old man with history of vaping who presented with fevers and night sweats for 1 week. (a) Coronal maximum intensity projection image shows diffuse centrilobular nodularity. (b) Histologic sections of his transbronchial cryobiopsy showed distinctive micronodular pattern of airway-centered organizing pneumonia, corresponding to centrilobular nodularity seen at CT. Similar imaging and pathologic findings have been described in patients with smoke synthetic cannabinoids. Image courtesy of Radiological Society of North America (RSNA)

News | Lung Cancer | January 28, 2020
January 28, 2020 — Pulmonary imaging is important in the diagnosis of the acute lung injury associated with...
Trends in Overall Cancer Mortality Rates by Sex, United States, 1930 to 2017. Rates are age adjusted to the 2000 US standard population

Trends in Overall Cancer Mortality Rates by Sex, United States, 1930 to 2017. Rates are age adjusted to the 2000 US standard population. Chart courtesy of the American Cancer Society

News | Radiation Oncology | January 13, 2020
January 13, 2020 — The cancer death rate declined